logo-loader

Shield Therapeutics PLC

Receive alerts
Market:
LSE
Market Cap:
£216.21 m
Price
184.50 GBX
Change
0.27%
52 weeks high
202.00
52 weeks low
30.00

 

 

Feraccru®

Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies.

For further information on Feraccru® please click here.
 

Pipeline product candidates

PT20

PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.

PT30 and PT40

PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.

Carl Sterrit
Chief Executive Officer and Co-Founder

James Karis
Non-Executive Director

Peter Llewellyn-Davies
Non-Executive Director

Rolf Hoffman
Non-Executive Director

Hans Peter Hasler
Non-Exectuive Director

Tim Watts
Interim CFO

Dr Mark Sampson
Chief Medical Officer

Dr Jackie Mitchell
VP Regulatory Affairs and Quality
 

David Childs
Director of Product Supply and Commercial Alliances

Lucy Bailey
Senior Legal Counsel and Company Secretary

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

e[email protected]

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

e[email protected]

Wollerau, Switzerland

Sihleggstrasse 23, 
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

e[email protected]

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

e[email protected]

 

Nominated Advisor and Joint Broker

Peel Hunt LLP, 120 London Wall London EC2Y 5ET

Tel: +44 (0)20 7418 8900

Joint Broker

finnCap, 60 New Broad Street London EC2M 1JJ

Tel: +44 (0)20 7220 0500

Auditors

KPMG LLP, Quayside House, 110 Quayside Newcastle Upon Tyne NE1 3DX

Tel: +44 (0)19 1401 3700

Legal Advisors

Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH

Tel: +44 (0)20 7329 4422

Tax Advisors

Ernst & Young LLP, Citygate St James’ Boulevard Newcastle upon Tyne NE1 4JD

Tel: +44 (0)19 1247 2500

Investor Relations and Financial PR

Walbrook PR Ltd, 4 Lombard Street London EC3V 9HD

Tel: +44 (0)20 7933 8780

Email: [email protected]

Registrar

Link Asset Services Limited, The Registry 34 Beckenham Road Beckenham Kent BR3 4TU

Tel: +44 (0)871 664 0300

Shield Therapeutics plc

Shield Therapeutics plc, Northern Design Centre Gateshead Quays, Gateshead NE8 3DF

Tel: +44 (0)191 511 8500

Email: [email protected]

 

Analyst Coverage

The following analysts currently issue reports on Shield Therapeutics:

Company                                                                           Analyst

Liberum                                                                              Graham Doyle

Peel Hunt                                                                           Amy Walker

Edison                                                                                Dr Susie Jana

Hardman & Co                                                                    Dr Dorothea Hill

Capital Network                                                                  Emma Ulker

finnCap                                                                               Mark Brewer

Click here to view share price summary.